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Abstract
Prostate cancer is the most common malignancy in men. In the present study, LNCaP (androgen-sensitive human prostate
cancer cells) and PC-3 cells (androgen-independent human prostate cancer cells) were used to investigate the anti-cancer
effects of ionizing radiation (IR) combined with arsenic trioxide (ATO) and to determine the underlying mechanisms in vitro
and in vivo. We found that IR combined with ATO increases the therapeutic efficacy compared to individual treatments in
LNCaP and PC-3 human prostate cancer cells. In addition, combined treatment showed enhanced reactive oxygen species
(ROS) generation compared to treatment with ATO or IR alone in PC-3 cells. Combined treatment induced autophagy and
apoptosis in LNCaP cells, and mainly induced autophagy in PC-3 cells. The cell death that was induced by the combined
treatment was primarily the result of inhibition of the Akt/mTOR signaling pathways. Furthermore, we found that the
combined treatment of cells pre-treated with 3-MA resulted in a significant change in AO-positive cells and cytotoxicity. In
an in vivo study, the combination treatment had anti-tumor growth effects. These novel findings suggest that combined
treatment is a potential therapeutic strategy not only for androgen-dependent prostate cancer but also for androgen-
independent prostate cancer.
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Introduction
Prostate cancer represents a major health problem for men
worldwide. Previous studies have demonstrated that the activation
of androgen receptors (AR) by androgens is required for the
growth and survival of prostate cancer cells. Furthermore, most
prostate tumors are androgen-dependent in the beginning [1].
However, over time, the tumor recurs in an androgen-refractory
manner and present with a more aggressive and metastatic
phenotype, which is resistant to further hormonal manipulation
[2]. Because androgens play important roles in the growth and
survival of prostate cancer cells, growing evidence suggests a
significant role for Akt in the development of hormone-
independent prostate disease [3,4,5]. The inhibition of Akt in
prostate cells abrogates HER-2/neu-induced AR signaling and
cell survival/growth effects in the absence or presence of androgen
[4]. Furthermore, successful progression to an androgen-indepen-
dent state requires intact PI3K signaling [6]. Thus, the inhibition
of the Akt pathway is emerging as an attractive clinical objective
for the prevention of hormone-refractory disease.
There is now abundant evidence supporting the benefits of
high-dose external beam radiotherapy in patients with clinically
localized prostate cancer [7]. However, high-dose radiotherapy
causes considerable collateral damage to normal cell populations
at the treatment site [8]. Thus, the use of chemical modifiers as
radiosensitizers in combination with low-dose irradiation may
increase the overall therapeutic efficacy. Arsenic has long been
used as anticancer agent in traditional Chinese medicine [9].
Recently arsenic trioxide (ATO) has been successfully employed in
the treatment of refractory or relapsed acute promyelocytic
leukemia (APL), and its efficacy has been confirmed even in
patients resistant to conventional chemotherapy [10]. Previous
studies have also demonstrated that the combination of ATO and
ionizing radiation (IR) is likely to be the most effective strategy for
leukemia and solid tumors [11,12,13]. ATO could serve as a
potent radiation sensitizer and may increase the cure rate of
malignant cells. However, the effects and the precise mechanism of
combined treatment of ATO and IR against prostate cancer
remain unclear.
Autophagy is one of the mechanisms of stress tolerance that
maintains cell viability and can lead to tumor dormancy,
progression and therapeutic resistance. However, many anticancer
drugs could also induce the excessive or prolonged autophagy that
triggers tumor cell death. Studies are ongoing to define optimal
strategies to modulate autophagy for cancer prevention and
therapy and to exploit autophagy as a target for anticancer drug
discovery [14]. A number of connections occur upstream of the
apoptotic and autophagic machinery, where signaling pathways
regulate both processes. Activation of the PI3 kinase/Akt pathway,
a well-known method to inhibit apoptosis, also inhibits autophagy
[15]. Akt is a serine/threonine protein kinase that plays a critical
role in suppressing apoptosis by regulating its downstream
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rapamycin (mTOR), which has been reported to inhibit the
induction of autophagy [17]. Both apoptosis and autophagy could
be induced in certain tumor cells under the treatment of anti-
cancer drugs [18,19].
Atorvastatin induces autophagy in the androgen receptor
negative prostate cancer PC-3 cells through the activation of
LC3 transcription [20]. In addition, a recent study has also
indicated that a natural BH3 mimetic ((2)-gossypol) induces
autophagy in apoptosis-resistant prostate cancer by modulating
Bcl-2-Beclin1 interaction at the endoplasmic reticulum [21].
Androgen-independent prostate cancer cells with higher levels of
Bcl-2 were more resistant to (2)-gossypol induced apoptosis.
However, (2)-gossypol induced similar levels of total cell death in
both androgen-dependent and -independent cells; it killed
androgen cells mainly through apoptosis, but in androgen-
independent cells, the mode of cell death was not fully understood
[21]. Recently, it was shown that ATO or IR can also induced
autophagy but not apoptosis in cancer cells [22,23].
In the present study, LNCaP (androgen-sensitive human
prostate cancer cells) and PC-3 cells (androgen-independent
human prostate cancer cells) were used to investigate the anti-
cancer effects of IR combined with ATO. The types of cell death
induced by IR combined with ATO were examined. We also
investigated the possible mechanisms underlying apoptosis or
autophagy in LNCaP and PC-3 cells induced by IR and/or ATO.
Materials and Methods
Cell culture and drug treatment
The human prostate cancer cell lines LNCaP (ATCC CRL-
1740) and PC-3 (ATCC CRL-1435) were obtained from the
American Type Culture Collection (ATCC). The cells were
cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY)
that was supplemented with antibiotics containing 100 U/ml
penicillin, 100 mg/ml streptomycin (Gibco BRL, Grand Island,
NY), and 10% fetal bovine serum (HyClone, South Logan, UT,
USA).Cells were incubated in a humidified atmosphere containing
5% CO2 at 37uC. Exponentially growing cells were detached with
0.05% trypsin-EDTA (Gibco BRL, Grand Island, NY) in RPMI
1640 medium. For exposure to arsenic trioxide (Sigma Chemical
Co.), 1 mM fresh stock solutions were prepared before every
experiment and filter-sterilized using a 0.2-mm syringe filter. The
reagent was added in a concentrated form to the culture medium
and mixed gently. The cultures were subsequently incubated for
the times indicated in the figures.
Treatment with irradiation and cell viability assay
IR was performed with 6 MV X-rays using a linear accelerator
(Digital M Mevatron Accelerator, Siemens Medical Systems, CA,
USA) at a dose rate of 5 Gy/min. An additional 2 cm of tissue-
equivalent bolus was placed on the top of a plastic tissue culture
flask to ensure electronic equilibrium, and 10 cm of tissue-
equivalent material was placed under the flask to obtain full back-
scatter. The treated cells were centrifuged and resuspended in
0.1 ml of PBS. Each cell suspension (0.02 ml) was mixed with
0.02 ml of trypan blue solution (0.2% in PBS). After 1 or 2 min,
each solution was placed on a hemocytometer, and the blue
stained cells were counted as non-intact.
Clonogenic assay
Cells were irradiated with 2, 4 or 6 Gy. ATO was added to cells at
concentrations of 2 or 5 mM. The cells were trypsinized and counted.
Known numbers of cells were subsequently replated in 6-cm culture
dishesandreturnedtotheincubatortoallowforcolonydevelopment.
After seven days, colonies (containing $50 cells) were stained with a
0.5% crystal violet solution for 30 min. Plating efficiency (PE) is the
ratio of the number of colonies to the number of cells seeded in the
nonirradiated group. Calculation of survival fractions (SFs) was
performed using the equation: SF=colonies counted/(cells see-
ded6PE), taking into consideration the individual PE.
Determination of early apoptosis
Apoptosis was assessed by observing the translocation of
phosphatidyl serine to the cell surface, as detected with an
Annexin V apoptosis detection kit (Calbiochem, San Diego, CA,
USA), according to our previous report [13].
Measurement of ROS production
Reactive oxygen species (ROS) production wasmonitored by flow
cytometry using 2,7-dichlorodihydrofluorescein diacetate (DCFH-
DA), as described previously [24]. After treatment with IR and/or
ATO, the cells were incubated with 20 mM of DCFH-DA for
30 min. The cells were harvested, washed once and resuspended in
PBS. Fluorescence was monitored using a flow cytometer.
Supravital cell staining with acridine orange for
autophagy detection
Cell staining with acridine orange (Sigma Chemical Co.) was
performed according to published procedures [13]. Cells were pre-
treated with autophagy inhibitors 3-methyladenine (3-MA) (Sigma
Chemical Co.) at a final concentration of 1 mM for 1 hr before IR
treatment.
Electron microscopy
Cells were fixed with a solution containing 2.5% glutaraldehyde
plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3,
for 1 hr. After fixation, the samples were postfixed in 1% OsO4 in
the same buffer for 30 min. Ultra-thin sections were subsequently
observed under a transmission electron microscope (JEOL JEM-
1200EX, Japan) at 100 kV.
Western blot analysis
Total cellular protein lysates were prepared by harvesting cells
in protein extraction buffer for 1 hr at 4uC, as described previously
[12]. The densities of the bands were quantified with a computer
densitometer (AlphaImager
TM 2200 System Alpha Innotech
Corporation, San Leandro, CA, USA). The expression of GAPDH
was used as the protein loading control. The antibodies for
detecting Akt, phospho-Akt, phospho-mTOR, phospho-p70S6K,
ERK, phospho-ERK, phospho-PDK1, PDK1, JNK, p38, phos-
pho-p38, Beclin 1, Bax and Bcl-2 were obtained from Cell
Signaling Technology (Ipswich, MA, USA); anti-GAPDH was
obtained from Abcam (Cambridge, MA, USA); LC3, Atg5 and
Atg5-12 were obtained from Abgent (San Diego, CA, USA); anti-
p62/SQSTM1 antibody was obtained from MBL (Nagoya,
Japan); anti-poly (ADP-ribose) polymerase (PARP) antibody was
obtained from Millipore (Billerica, MA, USA); mTOR, p70S6K,
phospho-JNK, caspase-3 and cleaved-caspase-3 were obtained
from Epitomics (Burlingame, CA, USA).
In vivo tumor growth assays using the PC-3 tumor model
in nude mice
All experiments on mice were performed according to the
guidelines of our institute (the Guide for Care and Use of
Laboratory Animals, National Cheng Kung University). The
animal use protocol listed below has been reviewed and approved
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(Approval No: 99138). Six- to eight week-old male nude mice
(BALB/cAnN.Cg-Foxn1
nu/CrlNarl) were acquired from the Na-
tional Laboratory Animal Center (Taiwan). The animals were
housed five per cage at 2462uC and 50%610% relative humidity
and subjected to a 12-h light/12-h dark cycle. The animals were
acclimatized for 1 week prior to the start of experiments and fed
withaPurinachowdietand wateradlibitum.Tumorswereinduced
by subcutaneous (s.c.) injection of PC-3 cells (2610
6 cells in 0.1 mL
of PBS) at one site of the right flank. Tumors (visualized as small
nodules at the sites of injection) appeared ,7 days after injection,
and the animals were randomly distributed into each group. Mice
were treated with: (1) vehicle (PBS), (2) 6 mg/kg ATO three times
per week for two weeks (on day 0, 2, 4, 7, 9 and 11), (3) a single dose
of 6 Gy IR, or (4) a combination treatment consisting of 6 mg/kg
ATO three times per week for two weeks started right after a single
dose of6 GyIR.Mousebodyweightsweremeasuredonceper week
and were used as an indicator of systemic toxicity of the treatment.
Tumorgrowthwasmeasured everytwodays,andthe tumorvolume
was calculated according to the formula shown below [25]:
Tumor volume mm3 
~larger diameter mm ðÞ |
small diameter mm ðÞ
2=2
Data are expressed as the relative tumor volume compared to the
pretreatment volume measured on day 0. The tumor volume
quadrupling time (TVQT, in days) was determined by a best-fit
regression analysis. The tumor growth delay (TGD) time is defined
as the difference between the TVQT of the treated tumors
compared with that of untreated control tumors. The TVQT and
TGD time were calculated for each individual mouse and averaged
for each group. Tumor growth inhibition rate was calculated as
follows: Inhibition (%)=(mean tumor volume of untreated control
mice2tumor volume of treated mice)/mean tumor volume of
untreated control mice6100.
Immunohistochemical (IHC) staining analysis
Paraffin-embedded tissue sections (4 mm) were dried, depar-
affinized, and rehydrated. After microwave pretreatment in citrate
buffer (pH 6.0; for antigen retrieval), the slides were immersed in
3% hydrogen peroxide for 20 min to block the activity of
endogenous peroxidase. After intensive washing with PBS, the
slides were incubated overnight at 4uC with the LC3 (MBL,
Japan), PCNA (ProteinTec Group, Inc., Chicago, USA) and Atg5
(Abgent, San Diego, CA, USA) antibodies. The sections were
incubated with a secondary antibody for 1 hr at room tempera-
ture, and the slides were developed with the STARR TREK
Universal HRP detection kit (Biocare medical, Concord, CA).
Finally, the slides were counterstained with hematoxylin. Each
slide was scanned at low power (6200).
Statistical analysis
Data areexpressed as the mean 6 SD. Statistical significance was
determined by using Student’s t-test for comparison between the
means or one-way analysis of variance with post-hoc Dunnett’s test
[26]. Differences were considered to be significant when p,0.05.
Results
Optimal dose and time selection of IR and ATO for
treatment of LNCaP and PC-3 cells
The viability of LNCaP and PC-3 cells was observed at different
doses of IR (0 to 8 Gy) for 6, 12, 18, 24 and 48 hrs (Fig. 1A).
Treatment with IR alone reduced the viability of the LNCaP and
PC-3 cells in a dose-dependent manner. Furthermore, the viability
of the cells was observed at different concentrations of ATO (0 to
15 mM) for 12, 24, 36 and 48 hrs (Fig. 1B). ATO alone reduced the
viability of cells in a concentration-dependent manner. After
treatment with 5 mM ATO for 48 hrs, the viability of LNCaP
and PC-3 cells was decreased to 60% and 73%, respectively.
Figure 1C shows the viability of ATO and IR treated alone or in
combination on LNCaP and PC-3 cells. Significantly enhanced
toxicity was found for the combination treatment compared with
ATO and IR treatment alone in LNCaP and PC-3 cells. Figures 1D
shows the radiation dose–response survival curves for LNCaP and
PC-3 cells with or without ATO treatment. The survival curves
dramatically shifted downward. ATO (2 mM) increased IR-induced
clonogenic cell death in LNCaP and PC-3 cells. ATO significantly
reduced the survival fraction in a dose-dependent manner
compared to IR alone.
Measurement of apoptosis in LNCaP and PC-3 cells
treated with ATO and IR alone or in combination
The induction of apoptotic cell death is a significant mechanism
of tumor cells under the influence of radio-/chemotherapy [27].
As shown in Figure 2A, early apoptosis in LNCaP and PC-3 cells
was measured by flow cytometry with the Annexin V apoptosis
detection kit. Quantitative results showed that the combination
treatment induced more apoptotic cell death than treatment alone
with ATO or IR in LNCaP cells. By contrast, the occurrence of
early apoptosis in PC-3 cells treated with ATO and/or IR was low
(less than 10%). ROS generation was further assessed by flow
cytometry. An approximately 3.5-fold increase in intracellular
peroxide levels was found when PC-3 cells were exposed to the
combination treatment for 1 hr (Figs. 2B, 2C). Figure 2D shows
the western blot analysis of poly (ADP-ribose) polymerase (PARP),
caspase-3, and Bcl-2. The cleavage of PARP by activated caspase-
3 results in the formation of an 85-kDa C-terminal fragment. Our
results showed that the specific cleavage of PARP and caspase-3
could be found in cells treated with IR, ATO alone or in
combination in LNCaP cells. We also analyzed the expression
level of Bcl-2, which is a suppressor of programmed cell death, and
found that the Bcl-2 proteins declined when treated with IR alone
and the combination treatment in both cells.
Measurement of autophagy in LNCaP and PC-3 cells
treated with ATO and IR alone or in combination
Autophagy is characterized by the formation of numerous acidic
vesicles, which are called acidic vesicular organelles (AVOs) [23].
Photomicrographs of AVOs were observed via green and red
fluorescence in acridine orange (AO)-stained cells with a
fluorescence microscope (Fig. 3A). The combined treatment
revealed a significant increase in AVOs compared to control
Figure 1. IR dose–response survival curves and cytotoxic effects resulting from ATO and IR in LNCaP and PC-3 cells. (A) Time-course
and dose-dependent effects of IR on the viability of LNCaP and PC-3 cells. Cells were treated with 2, 4, 6 or 8 Gy of IR for 6, 12, 18, 24 and 48 hrs. (B)
Time-course and concentration-dependent effects of ATO on the viability of LNCaP and PC-3 cells. Cells were treated with 2, 5, 10 or 15 mM of ATO for
12, 24, 36 and 48 hrs. (C) Cytotoxic effects of cells treated with IR (4 Gy) and ATO (5 mM). (D) The radiation dose–response survival curves of LNCaP
and PC-3 cells with or without ATO. Data are presented as the mean 6 standard deviation from three independent experiments.
doi:10.1371/journal.pone.0031579.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31579Figure 2. Measurement of apoptosis in LNCaP and PC-3 cells that received various treatments. (A) Early apoptosis detection was
measured by flow cytometry with an Annexin V apoptosis detection kit. Cells were treated with IR (4 Gy) and ATO (5 mM) for 48 hrs. #, p,0.05, IR
versus combined treatment. *, p,0.05, ATO versus combined treatment. (B) (C) ROS generation in PC-3 cells treated with 5 mM ATO or 4 Gy IR alone
or in combination for 30, 60, 120 min and with DCFH-DA for an additional 30 min. The fluorescence in the cells was immediately assayed using flow
cytometry. #, p,0.05, IR versus combined treatment. *, p,0.05, ATO versus combined treatment. (D) Western blotting of PARP, cleaved-PARP, pro-
caspase 3, cleaved-caspase 3and Bcl-2. The level of total GAPDH protein was used as the loading control. Cells were treated with IR (4 Gy) and ATO
(5 mM) for 48 hrs. Data are presented as the mean 6 standard deviation from three independent experiments.
doi:10.1371/journal.pone.0031579.g002
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cells for each treatment group were observed by EM photomi-
crography (Fig. 3B). The combined treatment also resulted in a
large number of autophagic vacuoles and autolysosomes in the
cytoplasm. In addition, there was no chromatin condensation or
nuclear pyknosis, which are characteristic of apoptosis, in any of
treated cells. Furthermore, AO staining was quantified using flow
cytometry (Figs. 3C, 3D). A significant increase in AO-positive
cells was found for cells receiving combined treatment compared
to those treated with IR or ATO alone in both cells. To detect the
expression of autophagy-related proteins, we performed western
blotting with lysates from LNCaP and PC-3 cells receiving each of
the different treatments (Fig. 3E, 3F). The expression levels of the
LC3-II, p62, Atg5 and Atg5-12 proteins increased with combined
treatment in both cells. The combined treatment induced
autophagy in LNCaP and PC-3 cells.
PI3K/Akt signaling pathway is involved in combined
treatment-induced cell death and cells undergo both
apoptotic and autophagic cell death when exposed to IR
and ATO in LNCaP and PC-3 cells
To investigate whether the PI3K/Akt signaling pathway was
involved in combined treatment-induced cell death, we performed
western blotting to detect the protein phosphorylation state
(Figs. 4A, 4B). Phosphorylated proteins that are related to the
PI3K/Aktsignalingpathwayswerealso examined.Theresultsshow
that phosphorylationofAkt, mTOR,p70S6KandPDK1decreased
in cells treated with the combined treatment compared with the
control. Next, we investigated whether the inhibition of autophagy
could change the percentage of viable cells that had been treated
with ATO and IR (Fig. 5). For this purpose, we utilized 3-
methyladenine (3-MA) (an autophagy inhibitor). Annexin V and
AO staining were quantified using flow cytometry. The combined
treatment of LNCaP and PC-3 cells pre-treated with 3-MA showed
no effectin apoptoticcells (Fig. 5C,5F), and a significant decrease in
AO-positive cells (Fig. 5B, 5E) compared to combined treatment.
Furthermore, we examined whether inhibition of autophagy could
alter the cytotoxicity of the combined treatment (Fig. 5A, 5D). We
found a significant decrease in cytotoxicity compared with the cells
receiving the combined treatment without pre-treatment with 3-
MA. These results suggest that ATO combined with IR can induce
autophagic cell death in LNCaP and PC-3 cells.
Tumor growth in nude mice was suppressed by IR and
ATO
Next, we next evaluated the anti-tumor growth effect of IR and
ATO in vivo. Tumors were induced by s.c. injection of PC-3 cells
into nude mice. We measured the body weight of the mice every
week and the tumor volume every two days. The results of this study
demonstrated that none of the treatment regimens produced any
loss of body weight, which may be a sign of toxicity (Fig. 6A). The
combined treatment suppressed tumor volume and tumor weight in
Figure 4. Effects of Akt/mTOR signaling pathway protein expression in LNCaP and PC-3 cells treated with IR and ATO alone or in
combination. Cells were treated with IR (4 Gy) and ATO (5 mM) for 48 hrs.
doi:10.1371/journal.pone.0031579.g004
Figure 3. Measurement of autophagy in LNCaP and PC-3 cells that received various treatments. (A) Microphotograph of AVOs in LNCaP
and PC-3 cells. Detection of green and red fluorescence in acridine orange (AO)-stained cells was performed using a fluorescence microscope. The
white arrows point to AVOs. (B) EM microphotographs of PC-3 cells treated with IR (4 Gy) and ATO (5 mM) for 48 hrs. The white arrows point to
autophagic vacuoles and autolysosomes. (C) Development of AVOs in LNCaP and PC-3 cells. Detection of green and red fluorescence in AO-stained
cells using flow cytometry. (D) Quantification of AVOs with AO-stained cells treated with IR (4 Gy) or ATO (5 mM) alone or in combination using flow
cytometry. Data are presented as the mean 6 standard deviation from three independent experiments. #, p,0.05, IR versus combined treatment. *,
p,0.05, ATO versus combined treatment. (E) (F) Western blotting of LC3-I, LC3-II, p62/SQSTM1, Atg5 and Atg5-12 expression in LNCaP and PC-3 cells.
Cells were treated with IR (4 Gy) and ATO (5 mM) for 48 hrs.
doi:10.1371/journal.pone.0031579.g003
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6C, 6D). As shown in Table 1, the tumor volume quadrupling time
(TVQT) of the control group was measured on Day 18 (17.962.2).
The tumor growth delay (TGD) time for the 18-day treatment of
ATO alone was 11 days, which was not significantly different than
for the control group (p=0.11). IR alone produced a TGD time of
8.965.1 days (p=0.17 compared to the control group). The
combination treatment resulted in a TGD time of 39.568.3 days
(p,0.05, compared with IR alone or ATO alone). The combination
therapy of IR and ATO resulted in a tumor growth inhibition of
74% on Day 18. Thus, the combination treatment possesses anti-
tumor growth effect in vivo. Next, the PCNA, LC3 and Atg5
expression pattern in the PC-3 tumors were examined by IHC
staining (Fig. 6E). PCNA expression was decreased and LC3 and
Atg5 were increased in the combined treatment compared with
ATO or IR treatment alone.
Discussion
Currently, the progression of prostate cancer to a state of
androgen independence remains the primary obstacle to improved
patient survival. Thus, novel treatment strategies that are useful for
androgen-independent disease need to be identified [28]. In the
present study, a combination of IR and ATO showed potential
as a therapeutic strategy for the treatment of prostate cancer
(androgen-dependent and-independent) (Fig. 1). Lian et al.
reported that the natural BH3-mimetic (2)-gossypol preferen-
tially induces autophagy in androgen-independent prostate
cancer cells that are resistant to apoptosis, whereas apoptosis is
preferentially induced in androgen-dependent cells [29]. The
present study shows that IR combined with ATO has an
increased therapeutic efficacy in LNCaP and PC-3 human
prostate cancer cells. Specifically, the combined treatment
induced autophagy and apoptosis in LNCaP cells, and mainly
induced autophagy in PC-3 cells (Figs. 1, 2, 3). The above in vitro
results are substantiated by in vivo experiments that employed a
mouse models with xenograft tumors from PC-3 cells. The
combined treatment suppressed tumor volume and tumor weight
in nude mice compared with ATO or IR treatment alone
(Fig. 6B). In addition, the combination therapy of IR and ATO
resulted in a tumor growth inhibition of 74% (Table 1).
Furthermore, the tumor tissues of LC3 and Atg5 expression
were increased in the combined treatment compared with ATO
or IR treatment alone (Fig. 6E).
Figure 5. Measurement of autophagy, apoptosis and cytotoxic effects in LNCaP and PC-3 cells pre-treated with 3-MA. (A)(D) Effects of
3-MA on cytotoxicity induced by combined treatment. (B)(E) Early apoptosis was measured by flow cytometry with Annexin V. (C)(F) Quantification of
AVOs with AO using flow cytometry. *, p,0.05, ATO+IR versus ATO+IR+3-MA.
doi:10.1371/journal.pone.0031579.g005
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patients require cessation of treatment due to side effects [30]. The
plasma level of arsenic in the clinical management of acute
promyelocytic leukemia usually reaches 5.5–7.3 mM [30]. It has
been reported that the peak concentration of plasma arsenic level
was 10.6 mM after intraperitoneal administration of 0.2 mg
(10 mg/kg) of ATO in mice [31]. The dosage used in our current
study was 6 mg/kg ATO in mice represent a concentration of
plasma arsenic level of 6.4 mM, which is clinically relevant.
Furthermore, our results in xenograft mouse model found that
there was no significant body weight loss in mice of combined
treatment compared to control group (Fig. 6A), and therefore
combined treatment procedure (6 mg/kg ATO three times per
week for two weeks and a single dose of 6 Gy IR) was well
tolerated.
The role of autophagy in cancer therapeutics is still controver-
sial. Autophagy has been found to play a role as a cell survival
mechanism that allows cells to clear damaged cytoplasmic proteins
and organelles through lysosomal degradation and to survive
metabolic stress [32]. On the other hand, autophagy has been
found to contribute to type II programmed cell death in response
to hypoxia, chemotherapeutic agents, viral infection, and toxins
[33]. Our results suggest that the observed significant increase in
autophagy can explain, at least in part, the cytotoxic effect of
combined treatment because pre-treatment with 3-MA, an
autophagy inhibitor, had a protective effect on combined
treatment–induced cell death in LNCaP and PC-3 cells (Figs. 3,
5). Recent studies have found that the Akt/mTOR pathway plays
a crucial role in the regulation of both apoptosis and autophagy
[34]. Ser473 is important for the recognition and phosphorylation
of Akt by PDK1 [35]. In addition, the antitumor effects of OSU-
03012, a celecoxib derivative, were thought to be mainly mediated
via the inhibition of PDK1 [36]. Disruption of the PI3K/Akt
pathway, culminating in inhibition of Akt, has been found to be
associated with autophagy induced by a variety of antineoplastic
agents in cancer cells [34]. A combination of indol-3-carbinol and
genistein synergistically induces apoptosis and autophagy in
human colon cancer HT-29 cells by inhibiting Akt phosphoryla-
tion [37]. Friedrichs et al. indicated that polyunsaturated fatty
acids can prevent the progression of prostate cancer cells to
hormone independence by modifying signal transduction path-
ways such as the Akt/mTOR pathway [28]. An intact PI3K/Akt
pathway is required for LNCaP cells to progress to hormone-
refractory state, and Akt activity increases as the cells transform
from hormone-dependent to hormone-independent [6]. The
present study demonstrates that the expression of p-Akt, p-
mTOR, p-p70S6K and p-PDK1 proteins decreased in cells
treated with IR combined with ATO compared to treatment with
ATO or IR alone (Fig. 4A).
Under oxidative stress, ROS, including free radicals, are
generated at levels sufficient to induce oxidation and damage to
DNA, lipids, proteins and other macromolecules [38,39]. On
occasion, autophagy and apoptosis both occur instantaneously
after stress; at other times, only autophagy or apoptosis is observed
[40]. ROS play a critical role in synergistic enhancement of
apoptotic cell death by the combination treatment with IR and
ATO in human cervical cancer cells [41]. It has been
demonstrated that the induction of apoptosis by the treatment of
cells with adenosine triggered caspase-3 activation, ROS forma-
tion and mitochondrial membrane potential (MMP) depletion in
prostate cancer cell lines [42]. Recently, several studies have
indicated that ROS may also be involved in the induction of
autophagy. The production of ROS, which is a result of the loss of
MMP, enhances the permeability of lysosomal membranes. This
increased permeabikity leads to the release of lysosomal proteases,
which contribute to mitochondrial membrane permeabilization
and the lysosomal degradation mechanism of autophagic cell
death [43]. H2O2 induces autophagy through interference with
the beclin-1 and Akt/mTOR signaling pathways, and is regulated
by the anti-apoptotic gene Bcl-2 in glioma U251 cells [44].
Phenethyl isothiocyanate triggers ROS to induce autophagy and
apoptosis in human prostate cancer cells [45]. Consistent with
these reports, we also found that combined treatment with ATO
and IR significantly increases ROS generation and consequently
induces autophagy in PC-3 cells (Figs. 2B, 2C). These results
indicate that ROS is critically involved in combined treatment-
induced cytotoxicity.
In conclusion, our results indicate that IR combined with ATO
increases the therapeutic efficacy compared to individual treat-
ments in LNCaP and PC-3 human prostate cancer cells.
Specifically, combined treatment induced autophagy and apopto-
sis in LNCaP cells, and mainly induced autophagy in PC-3 cells.
Table 1. Comparison of tumor growth inhibition, tumor volume quadrupling time, and tumor growth delay time of PC-3 tumors
in nude mice.
Number
of mice Inhibition
*(%)
Tumor volume
quadrupling time (days)
Tumor growth
delay time (days)
p value (t test)
#
Control ATO IR
Control 5 - 17.962.2 -
ATO (6 mg/kg66) 5 53.0611.4 29.065.4 11.165.4 0.11
IR (6 Gy) 5 61.4611.2 26.865.1 8.965.1 0.17 0.77
ATO+IR 5 74.469.9 47.468.3 39.568.3 ,0.05 ,0.05 ,0.05
*Tumor growth inhibition rate was calculated based on the tumor volume on Day 18.
#p values for comparison of tumor growth delay time.
doi:10.1371/journal.pone.0031579.t001
Figure 6. Tumor growth and body weight of tumor-bearing mice treated with IR (6 Gy) or ATO (6 mg/kg66) alone or in
combination. (A) Measurement of body weight in nude mice once per week. (B) Measurement of tumor volume in nude mice every two days. Data
are presented as the relative tumor volume (mean 6 standard error) normalized to the initial tumor volume measured on day 0. (C) Direct
observations of mice with tumors. After the experiments, the mice were sacrificed, and the tumors were removed. (D) Measurement of tumor weight
in the nude mice after sacrifice. (E) Immunohistochemical (IHC) staining of PC-3 mouse xenograft tissues. IHC was used to determine the expression
levels of PCNA, LC3 and Atg5 (6200 objective magnification).
doi:10.1371/journal.pone.0031579.g006
Arsenic Trioxide Enhances Radiation Sensitivity
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31579The combined treatment-induced cell death mainly occurred
through inhibition of the Akt/mTOR signaling pathways, and
ROS generation may be involved in the underlying mechanisms.
In a nude mouse tumor xenograft model, the combination
treatment possesses an anti-tumor growth effect. IR combined
with ATO could is a novel therapeutic method that may be for the
treatment of both androgen-dependent and -independent prostate
cancer.
Author Contributions
Conceived and designed the experiments: H-WC S-YH Y-JW. Performed
the experiments: H-WC Y-AC. Analyzed the data: H-WC Y-AC.
Contributed reagents/materials/analysis tools: H-WC Y-AC. Wrote the
paper: H-WC Y-JW.
References
1. Basu S, Tindall DJ (2010) Androgen action in prostate cancer. Horm Cancer 1:
223–228.
2. Dehm SM, Tindall DJ (2006) Molecular regulation of androgen action in
prostate cancer. J Cell Biochem 99: 333–344.
3. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, et al.
(2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen
receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:
9817–9824.
4. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, et al. (2000) HER-2/
neu promotes androgen-independent survival and growth of prostate cancer cells
through the Akt pathway. Cancer Res 60: 6841–6845.
5. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, et al.
(2011) Bortezomib represses HIF-1alpha protein expression and nuclear
accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in
prostate cancer cells. J Mol Med (Berl).
6. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ (2001) Role of PI3K
signaling in survival and progression of LNCaP prostate cancer cells to the
androgen refractory state. Endocrinology 142: 4795–4805.
7. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, et al. (2008) Long-term
results of conformal radiotherapy for prostate cancer: impact of dose escalation
on biochemical tumor control and distant metastases-free survival outcomes.
Int J Radiat Oncol Biol Phys 71: 1028–1033.
8. Probert JC, Parker BR (1975) The effects of radiation therapy on bone growth.
Radiology 114: 155–162.
9. Antman KH (2001) Introduction: the history of arsenic trioxide in cancer
therapy. Oncologist 6 Suppl 2: 1–2.
10. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, et al. (2001) Studies on the clinical
efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of
relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Leukemia 15: 735–741.
11. Kang YH, Lee SJ (2008) Role of p38 MAPK and JNK in enhanced cervical
cancer cell killing by the combination of arsenic trioxide and ionizing radiation.
Oncol Rep 20: 637–643.
12. Chiu HW, Ho SY, Guo HR, Wang YJ (2009) Combination treatment with
arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells
through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2
signaling pathways. Autophagy 5: 472–483.
13. Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ (2010) Combination treatment
with arsenic trioxide and irradiation enhances cell-killing effects in human
fibrosarcoma cells in vitro and in vivo through induction of both autophagy and
apoptosis. Autophagy 6: 353–365.
14. Yang ZJ, Chee CE, Huang S, Sinicrope F (2011) Autophagy modulation for
cancer therapy. Cancer Biol Ther 11: 169–176.
15. Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in
cancer. Nat Rev Cancer 7: 961–967.
16. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, et al. (2008) Transforming
growth factor beta induces apoptosis through repressing the phosphoinositide 3-
kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 68:
3152–3160.
17. Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in
cancer development and response to therapy. Nat Rev Cancer 5: 726–734.
18. Hsu KF, Wu CL, Huang SC, Wu CM, Hsiao JR, et al. (2009) Cathepsin L
mediates resveratrol-induced autophagy and apoptotic cell death in cervical
cancer cells. Autophagy 5: 451–460.
19. Qian W, Liu J, Jin J, Ni W, Xu W (2007) Arsenic trioxide induces not only
apoptosis but also autophagic cell death in leukemia cell lines via up-regulation
of Beclin-1. Leuk Res 31: 329–339.
20. Toepfer N, Childress C, Parikh A, Rukstalis D, Yang W (2011) Atorvastatin
induces autophagy in prostate cancer PC3 cells through activation of LC3
transcription. Cancer Biol Ther 12: 691–699.
21. Lian J, Wu X, He F, Karnak D, Tang W, et al. (2011) A natural BH3 mimetic
induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-
Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 18: 60–71.
22. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, et al. (2005) Arsenic
trioxide induces autophagic cell death in malignant glioma cells by upregulation
of mitochondrial cell death protein BNIP3. Oncogene 24: 980–991.
23. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, et al. (2001) A novel
response of cancer cells to radiation involves autophagy and formation of acidic
vesicles. Cancer Res 61: 439–444.
24. Ho SY, Chen WC, Chiu HW, Lai CS, Guo HR, et al. (2009) Combination
treatment with arsenic trioxide and irradiation enhances apoptotic effects in
U937 cells through increased mitotic arrest and ROS generation. Chem Biol
Interact 179: 304–313.
25. Osborne CK, Coronado EB, Robinson JP (1987) Human breast cancer in the
athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
Eur J Cancer Clin Oncol 23: 1189–1196.
26. Peng PL, Kuo WH, Tseng HC, Chou FP (2008) Synergistic tumor-killing effect
of radiation and berberine combined treatment in lung cancer: the contribution
of autophagic cell death. Int J Radiat Oncol Biol Phys 70: 529–542.
27. McDonnell TJ, Meyn RE, Robertson LE (1995) Implications of apoptotic cell
death regulation in cancer therapy. Semin Cancer Biol 6: 53–60.
28. Friedrichs W, Ruparel SB, Marciniak RA, Degraffenried L (2011) Omega-3
Fatty Acid Inhibition of Prostate Cancer Progression to Hormone Independence
Is Associated With Suppression of mTOR Signaling and Androgen Receptor
Expression. Nutr Cancer 63: 771–777.
29. Lian J, Karnak D, Xu L (2010) The Bcl-2-Beclin 1 interaction in (-)-gossypol-
induced autophagy versus apoptosis in prostate cancer cells. Autophagy 6:
1201–1203.
30. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II.
Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:
3354–3360.
31. Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, et al. (2002)
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to
facilitate long-term molecular remissions in mice with acute promyelocytic
leukemia. Proc Natl Acad Sci U S A 99: 9468–9473.
32. Corcelle EA, Puustinen P, Jaattela M (2009) Apoptosis and autophagy:
Targeting autophagy signalling in cancer cells –‘trick or treats’? FEBS J 276:
6084–6096.
33. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. (2006)
Autophagy promotes tumor cell survival and restricts necrosis, inflammation,
and tumorigenesis. Cancer Cell 10: 51–64.
34. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, et al. (2005)
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma
cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res
65: 3336–3346.
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
36. McCubrey JA, Lahair MM, Franklin RA (2006) OSU-03012 in the treatment of
glioblastoma. Mol Pharmacol 70: 437–439.
37. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, et al. (2009) A
combination of indol-3-carbinol and genistein synergistically induces apoptosis
in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and
progression of autophagy. Mol Cancer 8: 100.
38. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, et al. (2007) Distinct roles
of autophagy in the heart during ischemia and reperfusion: roles of AMP-
activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 100:
914–922.
39. Vorotnikova E, Rosenthal RA, Tries M, Doctrow SR, Braunhut SJ (2010) Novel
synthetic SOD/catalase mimetics can mitigate capillary endothelial cell
apoptosis caused by ionizing radiation. Radiat Res 173: 748–759.
40. Lockshin RA, Zakeri Z (2004) Apoptosis, autophagy, and more. Int J Biochem
Cell Biol 36: 2405–2419.
41. Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, et al. (2002) Enhancement of
radiation response in human cervical cancer cells in vitro and in vivo by arsenic
trioxide (As2O3). FEBS Lett 519: 195–200.
42. Aghaei M, Karami-Tehrani F, Panjehpour M, Salami S, Fallahian F (2011)
Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -
independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3.
Prostate.
43. Kim R, Emi M, Tanabe K, Murakami S, Uchida Y, et al. (2006) Regulation and
interplay of apoptotic and non-apoptotic cell death. J Pathol 208: 319–326.
44. Zhang H, Kong X, Kang J, Su J, Li Y, et al. (2009) Oxidative stress induces
parallel autophagy and mitochondria dysfunction in human glioma U251 cells.
Toxicol Sci 110: 376–388.
45. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, et al. (2010)
Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive
oxygen species-mediated death of human prostate cancer cells. J Biol Chem 285:
26558–26569.
Arsenic Trioxide Enhances Radiation Sensitivity
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31579